BioCentury
ARTICLE | Company News

Pfizer extends Lyrica exclusivity by six months in U.S.

November 30, 2018 8:30 PM UTC

Pfizer Inc. (NYSE:PFE) said FDA granted pediatric exclusivity to its blockbuster neurology drug Lyrica pregabalin, extending the product's patent protection by six months to June 30, 2019.

Lyrica is approved in the U.S. to treat fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles in adults; and as adjunctive therapy to treat partial onset seizures in patients four years of age and older...

BCIQ Company Profiles

Pfizer Inc.